

# Impact and cost-effectiveness of measles vaccination through microarray patches in 70 low-income and middle-income countries: mathematical modelling and early-stage economic evaluation

Han Fu <sup>1,2</sup> Kaja Abbas <sup>1,2,3,4</sup> Stefano Malvoti <sup>5</sup> Christopher Gregory,<sup>6</sup> Melissa Ko,<sup>5</sup> Jean-Pierre Amorij,<sup>7</sup> Mark Jit<sup>1,2,8</sup>

**To cite:** Fu H, Abbas K, Malvoti S, *et al.* Impact and cost-effectiveness of measles vaccination through microarray patches in 70 low-income and middle-income countries: mathematical modelling and early-stage economic evaluation. *BMJ Glob Health* 2023;**8**:e012204. doi:10.1136/bmjgh-2023-012204

**Handling editor** John Lee

► Additional supplemental material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/bmjgh-2023-012204>).

Received 6 March 2023

Accepted 1 October 2023



© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published by BMJ.

For numbered affiliations see end of article.

**Correspondence to**

Dr Han Fu; [Han.Fu@lshtm.ac.uk](mailto:Han.Fu@lshtm.ac.uk)

## ABSTRACT

**Background** Microarray patches (MAPs) are a promising technology being developed to reduce barriers to vaccine delivery based on needles and syringes (N&S). To address the evidence gap on the public health value of applying this potential technology to immunisation programmes, we evaluated the health impact on measles burden and cost-effectiveness of introducing measles-rubella MAPs (MR-MAPs) in 70 low-income and middle-income countries (LMICs).

**Methods** We used an age-structured dynamic model of measles transmission and vaccination to project measles cases, deaths and disability-adjusted life-years during 2030–2040. Compared with the baseline scenarios with continuing current N&S-based practice, we evaluated the introduction of MR-MAPs under different measles vaccine coverage projections and MR-MAP introduction strategies. Costs were calculated based on the ingredients approach, including direct cost of measles treatment, vaccine procurement and vaccine delivery. Model-based burden and cost estimates were derived for individual countries and country income groups. We compared the incremental cost-effectiveness ratios of introducing MR-MAPs to health opportunity costs.

**Results** MR-MAP introduction could prevent 27%–37% of measles burden between 2030 and 2040 in 70 LMICs, compared with the N&S-only immunisation strategy. The largest health impact could be achieved under lower coverage projection and accelerated introduction strategy, with 39 million measles cases averted. Measles treatment cost is a key driver of the net cost of introduction. In countries with a relatively higher income, introducing MR-MAPs could be a cost-saving intervention due to reduced treatment costs. Compared with country-specific health opportunity costs, introducing MR-MAPs would be cost-effective in 16%–81% of LMICs, depending on the MR-MAPs procurement prices and vaccine coverage projections.

**Conclusions** Introducing MR-MAPs in LMICs can be a cost-effective strategy to revitalise measles immunisation programmes with stagnant uptake and reach undervaccinated children. Sustainable introduction and uptake of MR-MAPs has the potential to improve vaccine

## WHAT IS ALREADY KNOWN ON THIS TOPIC

- ⇒ Microarray patches (MAPs) show great potential in overcoming vaccine delivery barriers in low-income and middle-income countries and are one of the leading innovative technologies selected by the Vaccine Innovation Prioritisation Strategy (VIPS).
- ⇒ Two measles-rubella MAP (MR-MAP) products are being evaluated for safety, tolerability and immunogenicity in phase I/II clinical trials and one of the products demonstrated positive trial results.
- ⇒ Despite the great potential, the health and cost impacts following the introduction of MR-MAPs in the current needle-based immunisation programmes still need to be determined.
- ⇒ Understanding the drivers associated with the cost-effectiveness of MR-MAPs will facilitate the development and implementation of MR-MAPs.

## WHAT THIS STUDY ADDS

- ⇒ Introducing MR-MAPs in low-income and middle-income countries will substantially reduce measles cases and deaths by reaching additional children and improving population immunity profiles.
- ⇒ There can be savings in the net cost following the MR-MAP introduction, especially in countries with a relatively high measles treatment cost being prevented.
- ⇒ The cost-effectiveness of MR-MAP introduction is sensitive to the assumptions of baseline coverage projections in the needle-based measles immunisation programmes and vaccine procurement prices for MR-MAP doses.

equity within and between countries and accelerate progress towards measles elimination.

## INTRODUCTION

As one of the essential childhood immunisations, measles-containing vaccines (MCV) has

### HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY

- ⇒ Continuing the development and implementation of MR-MAPs will bring benefits in reducing measles burden and addressing vaccine equity in low-income and middle-income settings.
- ⇒ Additional financial support or market incentives may be needed for vaccine procurement and sustainable implementation of MR-MAPs.
- ⇒ Understanding the health and cost impacts at an early stage of vaccine development provides helpful information for decision-makers to plan strategically for introducing MR-MAPs in country immunisation programmes.

been recommended by the WHO Expanded Programme on Immunisation since 1974.<sup>1</sup> The implementation of measles vaccination has brought substantial health benefits, with an estimated 33 million deaths averted between 2000 and 2019.<sup>2</sup> Maintaining high coverage (>95%) of two MCV doses is also recognised as a core strategy for measles elimination.<sup>3</sup> However, the uptake of the first dose of MCV was stagnant at 85% globally over 2011–2019, while measles outbreaks continued to occur, and measles remained a major public health burden in settings with low MCV coverage. The COVID-19 pandemic posed further challenges to national immunisation programmes, as seen in a 5% drop in the global coverage of the first MCV dose from 2019 to 2021.<sup>4,5</sup> The coverage of the second MCV dose has steadily increased and reached 72% in 2020, but its progress varies across countries and has stagnated in the last few years.<sup>5</sup>

Currently, MCVs are delivered via needle and syringe (N&S) vaccines. The traditional N&S presentation requires reconstitution before administration, and reconstituted doses that are not used within 6 hours are discarded. The delivery of N&S vaccines relies on trained healthcare workers for administration and demands a comprehensive and well-functioning cold chain system for storage and transportation. Addressing barriers to effective vaccine delivery associated with N&S vaccines could reduce global measles burden and accelerate progress in measles elimination.

Microarray patches (MAPs), a device containing hundreds to thousands of microprojections that deliver a vaccine dose into the dermis, has product characteristics that could address the barriers to vaccination presented by N&S. MAPs have demonstrated stability under higher temperatures for several vaccines, which reduces cold chain demand and potentially makes it easier to deliver vaccines to hard-to-reach areas.<sup>6,7</sup> In the absence of needles, injection applicators and reconstitution devices, MAPs could be operated by minimally trained staff or self-administered, which may expand the workforce to reach zero-dose children and underimmunised population.<sup>8</sup> MAPs are also broadly applicable in routine immunisation (RI) programmes and supplementary immunisation activities (SIAs). In low-income and middle-income countries (LMICs), implementing MAP technology may transform the current delivery of measles and rubella vaccines

in immunisation programmes and better reach under-served populations in remote rural or conflict-affected areas.<sup>9–11</sup> In May 2020, the Vaccine Innovation Prioritisation Strategy, a 3-year collaboration between Gavi, the Vaccine Alliance, WHO, Bill & Melinda Gates Foundation, UNICEF and PATH to develop a single integrated framework to evaluate, prioritise and drive forwards vaccine product innovations, selected MAPs as one of three technologies for prioritisation for development and implementation.<sup>8</sup>

As measles and rubella vaccines are jointly administered in most settings, a bivalent measles-rubella MAP (MR-MAP) is considered to have significantly broader use than a monovalent measles MAP.<sup>9</sup> MR-MAPs demonstrated both immunogenicity and safety in preclinical studies in infant rhesus macaques and provided effective protection against wild-type measles challenge.<sup>12</sup> Phase I/II trials of MR-MAPs were launched in The Gambia<sup>13</sup> and Australia<sup>14</sup>, and positive trial results demonstrated safety and similar immune responses to N&S vaccines.<sup>15</sup> Despite the early stage of clinical development, economic evaluation for MR-MAPs prior to phase III trials helps to determine the public health impact and economic case for further investment, as well as identify sources of uncertainties around the potential impacts to inform directions of data collection in the future.<sup>16</sup> Furthermore, early-stage economic evaluation can assess key determinants of cost-effectiveness and provide feedback on the MR-MAP product profile.<sup>17</sup>

In 2021, UNICEF commissioned MMGH Consulting in partnership with London School of Hygiene and Tropical Medicine and Global Health Visions to conduct an initial Full Value of Vaccine Assessment for MR-MAPs, to improve the assessment, decision-making and communication concerning MR-MAP development, procurement and implementation particularly for the use in LMICs. Placing end-users and stakeholders at the centre, the assessment aims to facilitate discussion and coordination between different perspectives and address various impacts on health, economy and society.<sup>18</sup> Analyses to understand the comprehensive value of MR-MAPs, including the total system costs, commercial business case and needs for market incentives, will be available in the report for the initial Full Value of Vaccines Assessment of MR-MAPs.<sup>19</sup> As part of the value assessment framework for MR-MAPs, this analysis focused on the health impact and cost-effectiveness of introducing MR-MAPs in LMICs, where more than 90% of global measles cases occurred.<sup>5</sup>

## METHODS

### Study setting

We included 70 LMICs in this global analysis of measles burden and vaccination, including 20 low-income countries, 35 lower-middle-income countries and 15 upper-middle-income countries based on the World Bank income classification for the fiscal year from July 2021 to June 2022.<sup>20</sup> We included all LMICs apart from those

having been verified for measles elimination and then kept their status until at least 2019 and those LMICs having  $\geq 95\%$  coverage with two doses of MCV and reporting  $\leq 5$  annual measles cases during 2017–2019. Additionally, we excluded countries that were projected to achieve a low level of measles burden in our analysis (see ‘Coverage projection’ section), defined as  $\leq 5$  annual cases over 2027–2029 and thus for which introducing MR-MAPs after 2030 would be expected to have only marginal benefit in burden reduction (Albania, Botswana, Cape Verde, Djibouti, Eritrea, Fiji, Georgia, Guinea, Guinea-Bissau, Jordan, Kazakhstan, Kuwait, Kyrgyzstan, Malaysia, Morocco, Mauritius, Rwanda, South Sudan, Thailand, Tonga and Vanuatu). The full list of countries included in the analysis can be found in online supplemental table A.

### Epidemiological model

We assessed the epidemiological impact of MR-MAPs introduction on measles burden in each country using Dynamic Measles Immunisation Calculation Engine (DynaMICE), for which a list of key parameters are included in online supplemental table B and a detailed description and application has been published.<sup>21</sup> DynaMICE is an age-structured compartmental model of measles transmission with states for people who are susceptible, infectious, recovered, protected by maternal antibodies and protected by immunisation. Measles transmission between age groups is simulated using country-specific social contact matrices<sup>22</sup> with a basic reproduction number of 15.9 based on a systematic review.<sup>23</sup> Case-fatality risks of measles are varied across countries and are relatively higher for children under 5 years old based on a recent review of available data.<sup>24</sup>

DynaMICE takes into account MCV coverage, efficacy, age at vaccination and vaccination history of targeted populations. In the model, RI programmes provide the first (MCV1) and second (MCV2) doses of measles vaccines to children aged 9 months and 16.5 months, respectively. SIAs are regularly scheduled for a population of a selected age range to enhance MCV coverage. We assumed SIA doses are delivered to children regardless of their vaccination history, except for up to 7.7% of children who are unreachable under current vaccination activities.<sup>25</sup> In the model, the efficacy of the first MCV dose increases linearly with the age of vaccine administration<sup>26</sup> and receiving two MCV doses provides 98% efficacy.<sup>27</sup> Vaccine protection was assumed to be all-or-nothing, that is, to offer complete protection to a proportion of the effectively vaccinated individuals and no protection to the rest.

### Coverage projection

Aligning with the approach used in Global Market Study for MCVs,<sup>28</sup> Ko *et al* projected global demand for MCV doses over 2030–2040 and developed use cases of MR-MAPs in needle-based immunisation programmes at the country level.<sup>29</sup> The forecasts were adapted

to coverage inputs and delivery components for the scenarios we evaluated in this cost-effectiveness analysis of introducing MR-MAPs.

To capture uncertainty in the future uptake of measles vaccination, especially given that countries are rebuilding health services disrupted by the COVID-19 pandemic, ‘higher’ and ‘lower’ coverage projections for MCV coverage were considered (table 1).<sup>29</sup> Under the higher coverage projection, current RI coverage for MCV1 and MCV2 is projected to increase by 0.5%–3% per year and capped at 95% or a higher level seen in the country-specific historical coverage; SIAs will take place every 2–5 years with a 95% coverage of children aged 9–59 months and will discontinue when MCV2 coverage exceeds 90% over three consecutive years. The growth rate of RI coverage and frequency of SIAs depend on country immunisation programmes. Under the lower coverage projection, where a less optimistic perspective is applied to the future programme expansion, projected RI coverage will remain constant at the 2019 level, and SIAs will reach only 85% of children.

### MR-MAP introduction

We modelled the effect of MR-MAP introduction in partially replacing N&S doses in existing immunisation programmes (components A, B and C in table 1) and reaching additional underserved populations for measles vaccination (components D, E and F). Following the assumptions in the demand forecast analysis,<sup>29</sup> the replacement of N&S doses with MR-MAP doses depends on the different MR-MAP use cases and on country-specific groupings reflective of the characteristics of their measles and rubella immunisation programmes (online supplemental table A). In countries where measles-mumps-rubella (MMR) vaccines are widely adopted in their existing immunisation programmes, no MR-MAP doses are anticipated to be used, as implementing separate monovalent mumps vaccines with MR-MAPs is less programmatically feasible. In countries which only partially offer or do not use MMR vaccines, 30% or 80% of the total MCV doses will be replaced with MR-MAPs. In addition, with improved product characteristics, MR-MAPs are assumed to reach extra populations living in hard-to-reach areas and children with missed opportunities for vaccination, with a coverage of 20% through RI activities (delivery components D and E) and 10% through one-off campaigns (component F) in the targeted age groups. The hard-to-reach populations include those in urban slums, security compromised, humanitarian settings and remote/rural areas, while 2% of children under 2 years old were assumed to experience missed opportunities for measles vaccination.

Two introduction strategies for MR-MAPs across countries were evaluated according to multiple factors, such as vaccine introduction history, disease burden and funding for immunisation programmes.<sup>29</sup> Under ‘sequential’ introduction, countries introduce MR-MAPs sequentially over the years between 2030 and 2040; those with higher

**Table 1** Assumptions for coverage forecasts and delivery components of measles vaccines

Delivery components and target population	Coverage projection of target population		Effect of MR-MAPs
	Higher coverage	Lower coverage	
A: MCV1 for children aged 9 months old, RI B: MCV2 for children aged 16.5 months old, RI	Annual growth depending on the overall coverage level: ▶ 3% per year for <70% ▶ 1% per year for 70%–85% ▶ 0.5% per year for >85% ▶ Capped at 95% or a higher level shown in the past programme	Stagnant coverage estimates at the 2019 level	Replace a country-specific proportion of N&S doses: ▶ 0% for major MMR use in their immunisation programmes ▶ 30% for partial MMR use ▶ 80% for no MMR use
C: SIA coverage for children aged 9–59 months old, campaign	Frequency depending on MCV2 coverage: ▶ Every 2 years for <60% ▶ Every 3 years for 60%–80% ▶ Every 4–5 years for >80% ▶ Discontinuation for >90% over three consecutive years Fixed coverage: 95%	Frequency is the same as under the ‘higher’ coverage projection assumptions. Fixed coverage of 85%	
D: MCV1 for children aged 1–2 years old with MOV or living in HTR areas, RI E: MCV2 for children aged 1–2 years old with MOV or living in HTR areas, RI	Fixed coverage: 20% of children experiencing MOV or living in HTR areas		Reach additional populations that were assumed not being reached with N&S vaccines.
F: One-time catch-up SIA for population aged 2–15 years old with MOV or living in HTR areas, campaign	Fixed coverage: 10% of children experiencing MOV or living in HTR areas		

Measles vaccine delivery is modelled through six components (A–F) with different age and vaccination status of target populations, coverage projection assumptions, delivery approaches (RI or campaign) and dose presentations (N&S or MR-MAP). Details of the parameters and data sources used in shaping these assumptions are included in the demand forecast analysis by Ko *et al.*<sup>29</sup> Introducing MR-MAPs was assumed to partially replace doses in the existing needle-based immunisation programmes with MR-MAPs (components A–C) and provide additional MR-MAP doses to children with MOV or living in HTR areas (components D–F). The level of replacement with MR-MAPs (market penetration) depends on the size of the different use cases for MR-MAPs and the characteristics of the measles and rubella programmes (inclusive of the use of MMR N&S vaccines) in each country.  
HTR, hard-to-reach; MCV1, the first routine dose of measles-containing vaccine; MMR, measles-mumps-rubella; MOV, missed opportunities for vaccination; MR-MAP, measles-rubella microarray patch; N&S, needle and syringe; RI, routine immunisation; SIA, supplementary immunisation activity.

measles and rubella burden and better operational and financial states for new vaccine introductions will adopt MR-MAPs in earlier years. Alternatively, ‘accelerated’ introduction allows countries with the greatest need, based on their MCV1 coverage and disease burden only, to be prioritised for MR-MAP introduction. In [figure 1](#), we present coverage forecasts under the sequential and accelerated strategies for MR-MAP introduction, higher and lower coverage projection assumptions, and different delivery components ([table 1](#)) in the Democratic Republic of the Congo. The coverage forecasts for all 70 LMICs are included in online supplemental file 2.


**Economic costs**

We took a health provider perspective and ingredients approach in estimating the costs under different MR-MAPs scenarios. [Table 2](#) shows unit costs of measles vaccine and treatment by country income level, with all

values inflated to 2020 US dollars using country-specific gross domestic product deflators.<sup>30 31</sup> For each scenario, the total cost  $tc_{i,t}$  (treatment cost and vaccination cost) at year  $t$  in country  $i$  is denoted as:

$$tc_{i,t} = c_i^{tx} \times m_{i,t} + \sum_p \left( \left( c_{i,p,RI}^{vac} + c_{i,t,RI}^{del} \right) \times d_{i,t,p,RI} + \left( c_{i,p,SIA}^{vac} + c_{i,SIA}^{del} \right) \times d_{i,t,p,SIA} \right)$$

$c_i^{tx}$  represents the treatment cost for each measles case specific to country income group, extrapolated from countries with available data through a literature review (see text B in online supplemental file 1 for details).  $p$  indicates different vaccine types characterised by dose presentation, vial size and valent type.  $c_{i,p,RI}^{vac}$  and  $c_{i,p,SIA}^{vac}$  represent the vaccine procurement prices per dose delivered through RI and SIA, with an adjustment of



**Figure 1** Coverage forecasts of measles vaccination in the Democratic Republic of the Congo over 2020–2040, through different delivery components (table 1). Circles with different colours show the coverage by scenarios, and vertical dashed lines represent the introduction years under the sequential (green) and accelerated (red) introduction. For components (A–C), coverage forecasts for the existing immunisation programmes (blue) are the same regardless of MR-MAP introduction strategies but different for higher (darker colours) and lower (lighter colours) coverage projection assumptions. These coverage forecasts refer to the proportions of the total population in the corresponding age groups. For components (D–F), the coverage forecasts refer to the proportions of children experiencing MOV or living in HTR areas that receive additional MR-MAP doses, and fixed coverage is assumed. HTR, hard-to-reach; MCV1, the first routine dose of measles-containing vaccine; MOV, missed opportunities for vaccination; MR-MAP, measles-rubella microarray patch; SIA, supplementary immunisation activities.

wastage rates specific to the vaccine types. The procurement prices for N&S vaccines were obtained from the Market Information for Access Vaccine Purchase Database over 2016–2020.<sup>32</sup> Taking the average price of MR N&S vaccines as the baseline, we estimated a potential range of prices for MR-MAPs by country income group and eligibility to receive Gavi funds. The ‘lower’ MR-MAP price reflected the increased manufacturing cost per dose for a single-dose vial compared with a multiple-dose vial, using the price data of hepatitis B vaccines as

a proxy. The difference in the cost for a prefilled syringe compared with a single-dose vial is considered in estimating the ‘upper’ MR-MAP price, based on the price information from pneumococcal conjugate vaccines (see text A in online supplemental file 1 for details).  $c_{i,l,RI}^{del}$  and  $c_{i,SIA}^{del}$  represent the vaccine delivery costs per dose for RI and SIA by income level. The marginal cost of delivering one routine MCV1 or MCV2 dose was assumed to increase with country-specific coverage forecasts, as higher coverage levels require extra resources for

**Table 2** Unit costs (2020 US\$) for measles vaccination and treatment by income level of countries

Cost type (per dose or per case)	Low income	Lower middle income	Upper middle income	Source and notes
N&S wastage-adjusted price, RI	Gavi-eligible countries, MR: 0.73/(1-0.15)= <b>0.86</b> (5-dose vial) 0.66/(1-0.4)= <b>1.10</b> (10-dose vial)	Gavi, MR: 0.82/(1-0.15)= <b>0.96</b> (5-dose vial) 0.66/(1-0.4)= <b>1.10</b> (10-dose vial) Non-Gavi, MR: 0.87/(1-0.15)= <b>1.02</b> (5-dose vial) 0.70/(1-0.4)= <b>1.17</b> (10-dose vial) Non-Gavi, MMR: 4.47/(1-0.01)= <b>4.52</b> (2-dose vial)	MR: 2.37/(1-0.01)= <b>2.39</b> (1-dose vial) 0.69/(1-0.15)= <b>0.81</b> (5-dose vial) 0.69/(1-0.4)= <b>1.15</b> (10-dose vial) MMR: 4.00/(1-0.01)= <b>4.04</b> (1-dose vial) 4.00/(1-0.01)= <b>4.04</b> (2-dose vial) 1.50/(1-0.15)= <b>1.76</b> (5-dose vial) 1.50/(1-0.4)= <b>2.50</b> (10-dose vial)	MI4A <sup>32</sup> 1-dose vial: 1% wastage 2-dose vial: 1% wastage 5-dose vial: 15% wastage 10-dose vial: 40% wastage
N&S wastage-adjusted price, SIA	Gavi, MR: 0.73/(1-0.1)= <b>0.81</b> (5-dose vial) 0.66/(1-0.1)= <b>0.73</b> (10-dose vial)	Gavi, MR: 0.82/(1-0.1)= <b>0.91</b> (5-dose vial) 0.66/(1-0.1)= <b>0.73</b> (10-dose vial) Non-Gavi, MR: 0.87/(1-0.1)= <b>0.97</b> (5-dose vial) 0.70/(1-0.1)= <b>0.78</b> (10-dose vial) Non-Gavi, MMR: 4.47/(1-0.01)= <b>4.52</b> (2-dose vial)	MR: 2.37/(1-0.01)= <b>2.39</b> (1-dose vial) 0.69/(1-0.1)= <b>0.77</b> (5-dose vial) 0.69/(1-0.1)= <b>0.77</b> (10-dose vial) MMR: 4.00/(1-0.01)= <b>4.04</b> (1-dose vial) 4.00/(1-0.01)= <b>4.04</b> (2-dose vial) 1.50/(1-0.1)= <b>1.67</b> (5-dose vial) 1.50/(1-0.1)= <b>1.67</b> (10-dose vial)	MI4A <sup>32</sup> 1-dose vial: 1% wastage 2-dose vial: 1% wastage 5-dose vial: 10% wastage 10-dose vial: 10% wastage
MR-MAP wastage-adjusted price, RI and SIA	1.29/(1-0.01)= <b>1.30</b> (lower) 2.92/(1-0.01)= <b>2.95</b> (upper)	Gavi: 1.29/(1-0.01)= <b>1.30</b> (lower) 2.92/(1-0.01)= <b>2.95</b> (upper) Non-Gavi: 1.48/(1-0.01)= <b>1.49</b> (lower) 3.36/(1-0.01)= <b>3.39</b> (upper)	2.63/(1-0.01)= <b>2.66</b> (lower) 5.20/(1-0.01)= <b>5.25</b> (upper)	1-dose vial: 1% wastage See text A in online supplemental file 1
Vaccine delivery cost, RI	2.02 plus 0.071 and 0.148 per 1% coverage increase for baseline coverage <80% and ≥80%	5.11 plus 0.177 and 0.272 per 1% coverage increase for baseline coverage <80% and ≥80%	6.45	Levin <i>et al</i> <sup>33</sup> Baseline coverage is set as 2020 projected coverage.
Vaccine delivery cost, SIA	0.91	1.89	1.97	Levin <i>et al</i> <sup>33</sup>
Measles treatment cost	10.9	120	235	See text B in online supplemental file 1

Unit costs per vaccine dose or per measles case are listed by income level and other factors specific to the type of costs. N&S vaccine procurement prices were extracted from the Market Information for Access Vaccine Purchase Database<sup>32</sup> by taking the median prices over 2016–2020, while MR-MAP prices were estimated using the N&S prices plus potential increases in manufacturing costs (text A in online supplemental file 1). Wastage rates were specified by dose package and delivery approaches (RI or SIA) and applied to adjust vaccine price, as: procurement price/(1-wastage rate). Wastage-adjusted vaccine prices are shown in bold values. Vaccine delivery costs are dependent on delivery approaches;<sup>33</sup> for RI, marginal delivery cost increases with baseline coverage since more resources are required to reach the underserved populations. Costs for treating measles-related illness were extracted from countries with available data through a literature review (text B in online supplemental file 1).

\*Prices from vials with a higher dose were used to ensure the inverse relationship between vial doses and costs.

MAPs, microarray patches; MI4A, Market Information for Access; MMR, measles-mumps-rubella; MR, measles-rubella; N&S, needle and syringe; RI, routine immunisation; SIA, supplementary immunisation activities.

unvaccinated children having the least access to immunisation services.<sup>33</sup> Finally, we multiplied these unit costs by the corresponding DynaMICE model estimates of  $m_{i,t}$  (the number of measles cases) and  $d_{i,t,p,RI}$  and  $d_{i,t,p,SIA}$  (the numbers of doses administered through RI and SIAs).

### Cost-effectiveness

Using DynaMICE, we estimated cases, deaths, disability-adjusted life-years (DALYs) and economic costs under the sequential and accelerated MR-MAP introduction

strategies and the baseline scenario without MR-MAPs. All the health and cost impact estimates were obtained at the country level and also totalled up by the World Bank income level for analysis.<sup>20</sup> For each country and income group, we calculated the incremental cost-effectiveness ratio (ICER) by dividing the total incremental costs by the total averted DALYs over 2030–2040 between the MR-MAP introduction scenarios and the baseline scenario. In the main analysis, a discount rate of 3% was applied equally for costs and health outcomes. We

also evaluated the ICERs under differential discounting, where only cost estimates were discounted at 3%, and health outcomes were not discounted, as recommended in the WHO guidelines for economic evaluation of immunisation programmes.<sup>34</sup> Since GDP-based thresholds are no longer recommended by WHO,<sup>35</sup> we instead used the thresholds estimated from the empirical data on opportunity costs of healthcare expenditure<sup>36 37</sup> to determine the cost-effectiveness of introducing MR-MAPs at the country level. As for the income-level ICERs, the thresholds were derived from population-weighted health opportunity costs in countries of the corresponding income groups (online supplemental figure A). In addition, we calculated the maximum MR-MAP procurement price that each country or income setting could afford to pay for the MR-MAP introduction while ensuring the introduction is cost-effective (compared with health opportunity cost thresholds). This price calculation was conducted with the assumption that the health gains during 2030–2040 from preventing measles illness, vaccine wastage rates, and all the other types of costs are held fixed under equal discounting.

### Patient and public involvement


Patients were not involved in this research. Representatives from country health departments and global health

institutes are among the stakeholders involved in the external advisory group of the initial Full Vaccine Value Assessment for MR-MAPs over the study design and reporting phases.

## RESULTS

### Health impact of MR-MAPs introduction

Introduction of MR-MAPs would result in measles burden reductions across all country income levels and assumptions about coverage projections (figure 2). Under the higher coverage projection, 21.3 million cases, 197 thousand deaths and 12.4 million DALYs due to measles are projected to occur over 2030–2040 across all the study countries if MR-MAPs are not available. Sequential introduction of MR-MAPs will result in 14.4 million measles cases, 145 thousand deaths and 9.01 million DALYs, as accelerated introduction will result in 13.9 million measles cases, 139 thousand deaths and 8.69 million DALYs. Countries in the lower-middle-income group contribute most to the global burden. The scale of the cumulative burden under the lower coverage projection is larger than the higher coverage projection, while the relative burden trends between different introduction strategies are similar. Under the lower coverage projection, there are estimated 106 million measles cases,



**Figure 2** Cumulative measles cases, deaths and DALYs in millions over 2030–2040 by income group levels and coverage projection assumptions. DALY, disability-adjusted life-year; MR-MAP, measles-rubella microarray patch.

1.15 million deaths and 74.0 million DALYs if MR-MAPs are not available, and 67.1 million measles cases, 750 thousand deaths and 47.7 million DALYs with accelerated MR-MAP introduction.

Table 3 shows MR-MAP introduction will reduce the total measles burden in 70 LMICs over 2030–2040 by 27%–37%. At the global level, the relative health impact of introducing MR-MAPs is similar between the higher and lower coverage projection assumptions. However, the absolute impact varies, with 6.96–7.45 million and 31.3–38.6 million measles cases being averted by MR-MAP introduction under the higher and lower coverage projection assumptions, respectively. Overall, the accelerated introduction of MR-MAPs in key countries is projected to be more effective in reducing measles burden than the sequential introduction, since those countries with higher burden are more likely to benefit from the early introduction of MR-MAPs. For individual countries, introducing MR-MAPs will result in reduction of health burden over 2030–2040, although some variation remains within the same income group level. We further analysed the exceptional countries and scenarios showing increased health burden following the MR-MAP introduction and found health benefits of MR-MAP introduction with an extended assessment period. This suggested that a longer time horizon would be needed to observe the complete health impacts of introducing MR-MAPs.

**Economic cost of MR-MAP introduction**


Figure 3 illustrates the breakdown of incremental costs following MR-MAP introduction, compared with the baseline scenario without MR-MAPs. The introduction of MR-MAPs will reduce costs for the existing immunisation service based on N&S vaccines, which will be partly replaced with MR-MAP doses. However, the reduction will not exceed the increase in costs of purchasing and delivering MR-MAPs, since introducing MR-MAPs will deliver extra doses to children experiencing missed opportunities for vaccination and living in hard-to-reach areas (delivery components D–F in table 1). Savings from treating measles-associated illness after the MR-MAP introduction were seen in all country income groups but relatively small compared with other cost types in the low-income setting. Overall, introducing MR-MAPs will be cost saving in the lower-middle-income and upper-middle-income settings provided at the lower MR-MAP procurement price under the lower coverage projection assumption (online supplemental table C) due to avoiding the high costs in these countries associated with measles treatment. In the low-income setting, the total incremental costs will increase across all the scenarios for evaluation. Unlike the MR-MAP price, the introduction strategies had little implications in the scale and direction of incremental costs. At the country level, the incremental costs following the introduction of MR-MAPs show a large variation within the same income group,

**Table 3** Averted measles burden (in thousands) following the introduction of MR-MAPs

Projection assumption	Higher coverage						Lower coverage					
	Sequential			Accelerated			Sequential			Accelerated		
	Measurement	Cases	Deaths	DALYs	Cases	Deaths	DALYs	Cases	Deaths	DALYs	Cases	Deaths
Low income	1076 (20.4%)	11.4 (22.6%)	742 (22.2%)	1116 (21.1%)	11.3 (22.5%)	739 (22.1%)	13004 (36.7%)	164 (38.3%)	11075 (38.6%)	14465 (40.8%)	176 (41.2%)	11851 (41.3%)
Lower middle income	5000 (34.2%)	38.1 (27.0%)	2494 (28.6%)	5452 (37.3%)	43.4 (30.8%)	2815 (32.3%)	16905 (26.5%)	218 (31.9%)	13612 (31.7%)	23063 (36.2%)	220 (32.1%)	14014 (32.7%)
Upper middle income	887 (61.9%)	2.85 (50.7%)	185 (50.7%)	884 (61.7%)	2.83 (50.4%)	184 (50.4%)	1350 (20.8%)	7.70 (21.7%)	517 (21.9%)	1094 (16.9%)	5.88 (16.6%)	395 (16.8%)
Total	6963 (32.7%)	52.3 (26.6%)	3420 (27.5%)	7452 (35.0%)	57.6 (29.2%)	3737 (30.1%)	31259 (29.6%)	390 (34.0%)	25204 (34.1%)	38623 (36.5%)	402 (35.0%)	26260 (35.5%)

Numbers represent the absolute cases, deaths and DALYs averted in thousands. Percentages in the brackets show the relative burden reduction compared with the scenarios without MR-MAPs. DALY, disability-adjusted life-year; MR-MAP, measles-rubella microarray patch.





**Figure 3** Breakdown of incremental costs following MR-MAP introduction under the assumptions of higher coverage projection (A) and lower coverage projection (B). For each horizontal bar, incremental costs of measles treatment, vaccine procurement and vaccine delivery are stacked and denoted in different colours. Hollow circles represent overall incremental costs. The vertical line is set at zero; to its left, negative values (purple and yellow bars) indicate savings following the MR-MAPs introduction, while to its right, positive values (green bars) indicate increased costs. DALY, disability-adjusted life-year; MR-MAP, measles-rubella microarray patch; N&S, needle and syringe.


as a result of country heterogeneities in dose demand, measles burden and vaccine procurement costs.

### Cost-effectiveness of MR-MAP introduction

Figure 4 shows the income group level ICERs of introducing MR-MAPs by different assumptions for discounting, coverage projection, introduction strategy and MR-MAP price. The ICERs lie between US\$10.6 and US\$1850 per DALY averted in the low-income group, between -US\$108 and US\$1100 in the lower-middle-income group and between -US\$134 and US\$1210 in the upper-middle-income group. Negative ICER values corresponding to settings where it is cost saving to introduce MR-MAPs are mostly seen in the upper-middle-income group with the lower MR-MAP price. In the lower-middle-income group, introducing MR-MAPs would be cost-effective under the lower coverage projection. Under the higher coverage projection, it would not be cost-effective with an upper MR-MAP price using equal discounting but cost-effective using differential discounting. In the low-income group, introducing MR-MAPs would only be cost-effective under the lower coverage projection, regardless of the set price for MR-MAPs. Assumptions about the introduction strategy

resulted in smaller variations in the ICER estimates among low-income, lower-middle-income and upper-middle-income country groups.

Evaluating at the country level, we found similarity to the income-level analysis in factors that affect the cost-effectiveness of introducing MR-MAPs. MR-MAP introduction would be less likely to be cost-effective in countries with a lower income, despite wide variation within each income group (online supplemental figure B). With a 3% discount rate for both health and cost impacts, the introduction of MR-MAPs over 2030–2040 is considered cost-effective in 26%–81% and 16%–61% of analysed countries under the lower and upper MR-MAP prices, respectively (table 4). Alternatively, when applying differential discount rates, MR-MAP introduction would be cost-effective in 30%–81% and 19%–71% of countries under a lower and higher assumed price, respectively (online supplemental table D). The assumptions about coverage projection had the greatest influence on the cost-effectiveness of the MR-MAP introduction. Meanwhile, the procurement cost for MR-MAPs was influential on its cost-effectiveness in lower-middle-income countries. Introducing MR-MAPs will be most cost-effective



**Figure 4** Income group level ICERs of introducing MR-MAPs using equal discounting (A) and differential discounting (B) approaches. Equal discounting applies a 3% rate to both costs and health outcomes (averted DALYs), while differential discounting applies a 3% rate only to costs and no discounting of health outcomes. Circles and triangles denote the ICERs with the lower and upper MR-MAP prices, respectively. Colours represent the sequential (green) and accelerated (red) introduction strategies and assumptions of higher (darker) and lower (lighter) coverage projections. Horizontal dashed lines indicate the cost-effectiveness thresholds at the income group level; for scenarios with an ICER below the lines, it would be cost-effective to introduce MR-MAPs. DALY, disability-adjusted life-years; ICER, incremental cost-effectiveness ratio; MR-MAP, measles-rubella microarray patch.

**Table 4** Number of countries where introducing MR-MAPs is cost-effective

Projection assumption	Higher coverage				Lower coverage			
	Sequential		Accelerated		Sequential		Accelerated	
MR-MAP price	Lower	Upper	Lower	Upper	Lower	Upper	Lower	Upper
Low income	3/20	0/20	3/20	0/20	17/20	9/20	18/20	10/20
Lower middle income	10/35	6/35	9/35	5/35	25/35	20/35	28/35	22/35
Upper middle income	5/15	5/15	7/15	6/15	11/15	11/15	11/15	11/15
Total	18/70	11/70	19/70	11/70	53/70	40/70	57/70	43/70

Introducing MR-MAPs is considered to be cost-effective if the country-specific ICER is below the country-specific threshold, under a 3% annual discount rate on both incremental costs and health benefits.

ICER, incremental cost-effectiveness ratio; MR-MAP, measles-rubella microarray patch.

**Table 5** Wastage-adjusted MR-MAP price thresholds (2020 US\$) for introducing MR-MAPs to be cost-effective

Projection assumption	Higher coverage		Lower coverage	
	Sequential	Accelerated	Sequential	Accelerated
Low income				
Income group level	0.764	0.709	5.89	5.47
Country level	0.123–2.32 (n=19)	0.041–2.51 (n=19)	0.397–18.1 (n=19)	0.586–18.1 (n=19)
Lower middle income				
Income group level	2.67	2.17	14.7	11.6
Country level	0.012–37.9 (n=25)	0.051–40.7 (n=27)	0.086–39.6 (n=31)	0.572–72.0 (n=29)
Upper middle income				
Income group level	23.9	27.4	76.6	67.2
Country level	0.658–353 (n=10)	0.635–389 (n=9)	0.586–3310 (n=12)	0.579–1730 (n=12)

Numbers represent the wastage-adjusted price thresholds for introducing MR-MAPs to be cost-effective at the income group level and the country level under different coverage projection assumptions and introduction strategies. At the country level, the ranges of price thresholds are presented, with n in the brackets denoting the number of countries except for those where introducing MR-MAPs will not be cost-effective even if the procurement of MR-MAPs is at zero cost. The price thresholds were calculated while the health burden estimates, vaccine wastage rates and other cost inputs were assumed fixed. If an MR-MAP dose is provided at a procurement price above the threshold, it implies that introducing MR-MAPs would not be cost-effective.  
MR-MAP, measles-rubella microarray patch.

when provided through accelerated introduction with a lower MR-MAP price.

The maximum per MR-MAP dose procurement prices (2020 US\$) that ensure the cost-effectiveness of introducing MR-MAPs increase with the income group level (table 5). The price thresholds for MR-MAPs are consistently higher compared with the corresponding prices for N&S vaccines (table 2). Under the lower coverage projection, the maximum MR-MAP prices are higher because of larger health benefits and savings from averting measles burden. In the low-income and lower-middle-income settings, the price thresholds for MR-MAPs were lower under the accelerated introduction strategy than the sequential strategy. While the accelerated introduction will bring greater health benefits, per-dose vaccine delivery cost will also increase with higher coverage, resulting in overall reduction in cost-effectiveness, particularly several years after the MR-MAP introduction. As seen in the model-based health and cost impact estimates, the threshold prices across countries also result in great variability. In some countries, introducing MR-MAPs was found not to be cost-effective even if the procurement of MR-MAPs is zero price. These countries mostly have high measles vaccine coverage forecasts and only contributed to a small proportion (8%) of the total measles burden in the 70 LMICs between 2030 and 2040. Moreover, our price threshold analysis did not consider the potential reduction in delivery costs for MR-MAPs, which could improve the cost-effectiveness of the MR-MAP introduction.

## DISCUSSION

Our modelling analysis suggests that the introduction of MR-MAPs will bring substantial health benefits over

2030–2040 and is likely to be cost-effective in 16%–81% of LMICs, depending on the assumptions used. The strategy of accelerating MR-MAP introduction in high-burden countries generates the largest burden reduction compared with sequential introduction globally, despite requiring delayed introduction in lower-burden countries. Assumptions about the underlying MCV coverage growth in the future have a great influence on the magnitude of health impacts from introducing MR-MAPs, where the lower coverage projection resulted in larger numbers of averted cases, deaths and DALYs. Additionally, among the different types of costs, the cost for treating measles illness has a key role in the total expenditure and savings on treatment costs could surpass the incremental costs for the MR-MAP introduction, especially in countries with a higher income. For each country, the cost-effectiveness of introducing MR-MAPs will largely depend on the procurement price of an MR-MAP dose.

To our knowledge, our study is the first cost-effectiveness assessment at a global scale on the potential impact of the MR-MAP introduction. A previous study by Adhikari *et al* found that replacing traditional N&Ss with MAPs for measles immunisation is cost-effective in a hypothetical population, due to cost reductions in cold chains, personnel, injection equipment and needle disposal.<sup>38</sup> However, the detailed cost changes following the introduction of MR-MAPs would need more empirical research and data to estimate. Additionally, Adhikari *et al* assumed no changes in the total administered doses,<sup>38</sup> while we focused on the possible integration of MR-MAPs into existing immunisation programmes, with partial penetration of the N&S market and additional vaccine delivery to the populations living in hard-to-reach areas and experiencing missed opportunities of vaccination. We

considered both the cost and health aspects of MR-MAPs and included the health benefits of reaching previously underimmunised populations.

Assumptions about future coverage projections exert the greatest influence on the health impact of MR-MAPs among the assumptions examined in this study. The wide range between the lower and higher coverage projection assumptions aims to reflect the multiple sources of uncertainties around the future progress of national immunisation programmes and measles elimination efforts. The pessimistic lower coverage projection scenario may not capture worst-case situations such as those caused by funding instability, emerging diseases, natural disasters and political conflicts. Such situations could cause MCV coverage not just to stagnate, but to drop below what has been achieved historically, as seen in the global coverage estimate that reduced from 84% in 2020 to 81% in 2021 following the COVID-19 pandemic.<sup>5</sup> The role of MR-MAPs could be even more critical in measles immunisation when the future performance of immunisation programmes cannot meet the historical levels of coverage. In addition, our analysis shows a potentially substantial impact on measles burden reduction with a 10%–20% increase in coverage from providing MR-MAPs to populations living in hard-to-reach areas and experiencing missed opportunities for vaccination. With further reach to these underimmunised populations, MR-MAPs would realise even greater benefits in reducing measles burden.

To estimate the incremental cost of MR-MAPs introduction, we varied vaccine procurement costs, delivery costs and measles treatment costs by country income level. However, we assumed that delivery costs were the same for N&Ss and MR-MAPs, which may underestimate the potential of MR-MAPs to save costs from health personnel capacity and cold chain equipment.<sup>38</sup> On the other hand, integration of MR-MAPs into existing immunisation programmes will require structural changes in staffing and operation. There are uncertainties in estimating the delivery costs of MR-MAPs. Collecting the cost data, even at an early stage of vaccine development and licensure, will be useful in informing the investment case of future introduction. Indirect costs were not systematically included in this study. Patient costs for travel and waiting time during vaccination visits were included in a few original data sources, but productivity costs around the treatment of measles-associated illness were not considered.<sup>33</sup> From a societal perspective, including productivity loss would make the introduction of MR-MAPs more cost-effective. Although MR-MAP introduction was not considered cost-effective in some upper-middle-income settings from the perspective of measles burden reduction, their ability to reach underimmunised populations may still drive the introduction in order to reach regional measles elimination goals earlier. Furthermore, the impact of an earlier national/regional measles elimination, with the respective savings including reduced future demand for measles vaccines, was not considered in the cost-effectiveness analysis and

may further increase the cost-effectiveness of MR-MAP introduction.

There are other limitations in the cost-effectiveness analysis. First, we estimated the health burden following MR-MAP introduction based on country-level data and models, but some of the largest disparities in vaccine coverage exist at the subnational level such as in remote rural areas or border regions.<sup>39</sup> We did not investigate whether subnational targeting of MR-MAPs may achieve most of the coverage improvements at reduced cost. Second, we assessed the health and economic benefits of measles burden reduction following the introduction of MR-MAPs but excluded the concurrent reduction in rubella burden. Taking into account the impact on rubella burden will make the introduction of MR-MAPs more cost-effective. Nonetheless, the additional benefits may not be substantial compared with the reduction in measles burden since rubella is less transmissible and typically less severe than measles. Third, measles control measures apart from vaccination, such as contact tracing, self-quarantine and postexposure prophylaxis, were not included in the epidemiological modelling. This may affect both the cost and burden estimates, particularly in countries close to elimination.<sup>40</sup> However, their effect may be more limited in the high-burden countries that we examined. Fourth, in LMICs with fast economic growth, the assumption of a 3% discount rate may overvalue future costs and health benefits.<sup>41</sup> Nonetheless, it is challenging to project future economic growth to inform the discount rate for health interventions, given the uncertainty and complexity of the political and social context in the post-COVID-19 pandemic era. Finally, cost-effectiveness thresholds based on health opportunity costs may be useful in reflecting the value for money from a fixed budget perspective, but the methodology for this estimation has not yet been maturely developed, and only few countries have adopted these thresholds explicitly in decision-making for health policies.<sup>42</sup> Other context-specific considerations may also be decisive factors in the funding and implementation of MR-MAPs, and WHO recommends against basing health investment decisions purely on comparison to a cost-effectiveness threshold.<sup>35 43 44</sup>

This early-stage cost-effectiveness analysis was conducted from the perspective of the funder, for example, the country or pooled procurement donors such as Gavi. The examination of the return to the manufacturer on the investment needed for research and development before MR-MAPs enter the market, and the net present value of MR-MAPs are concurrently developed in the initial Full Value of Vaccines Assessment of MR-MAPs and will be reported.<sup>19</sup> Our analysis of the cost-effectiveness, including the calculated price thresholds for MR-MAPs, may inform vaccine investment entities such as the Vaccine Innovation Prioritisation Strategy about strategies to increase manufacturers' incentives to develop and market MR-MAPs, in order to achieve the projected health impact. While MR-MAPs are still in the early

stage of clinical development, this analysis can provide initial but comprehensive evidence that policy-makers can apply to understand the potential cost-effectiveness of MR-MAPs at the global level and/or national level and consider the implementation of MR-MAPs in their longer-term measles vaccination strategies.

In conclusion, this study has shown that there are substantial health benefits from introducing MR-MAPs in LMICs, particularly if countries bearing greater measles burden can be prioritised, as evaluated in the scenario with accelerated introduction. In addition to the reduction in measles burden, MR-MAP introduction would accelerate progress towards measles elimination more effectively and equitably through reaching underserved populations of children with missed opportunities for vaccination or living in hard-to-reach areas. Introducing MR-MAPs is also cost-effective in most LMICs, while external funding from donors could support the MR-MAP introduction in countries where it is not cost-effective under fixed domestic budgets. Although several assumed features of MR-MAPs are still highly uncertain, this early-stage evaluation can help inform key data gaps in assessing the cost-effectiveness of MR-MAPs, including future MCV coverage assumptions, MR-MAP ability to reach zero-dose and underimmunised children, procurement prices and country-specific costs for measles treatment and vaccine delivery. Addressing these data gaps will facilitate evidence generation for decision-making on MR-MAP introductions in LMICs.

#### Author affiliations

<sup>1</sup>Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK

<sup>2</sup>Centre for Mathematical Modelling of Infectious Diseases, London School of Hygiene & Tropical Medicine, London, UK

<sup>3</sup>Public Health Foundation of India, New Delhi, India

<sup>4</sup>School of Tropical Medicine and Global Health, Nagasaki University, Nagasaki, Japan

<sup>5</sup>MMGH Consulting GmbH, Zurich, Switzerland

<sup>6</sup>Immunization Unit, Programme Division, UNICEF, New York, New York, USA

<sup>7</sup>Supply Division, Vaccine Centre, UNICEF, Copenhagen, Denmark

<sup>8</sup>School of Public Health, The University of Hong Kong, Hong Kong SAR, People's Republic of China

**Acknowledgements** We thank Simon Procter at London School of Hygiene and Tropical Medicine, Jessica Ochalek at York University, and Adam Soble, Thomas Cherian, and Carsten Mantel at MMGH Consulting for helpful discussions. We acknowledge the feedback from members of the External Advisory Group of the initial Full Vaccine Value Assessment for MR-MAPs and the WHO Immunisation and Vaccine-related Implementation Research Advisory Committee.

**Contributors** KA, J-PA, MK and MJ conceptualised the study framework. HF, SM and MK curated the input data for analysis. HF and MK conducted the analysis. HF developed the computer codes, visualised the results, and wrote the first draft of the manuscript. J-PA, MK and MJ supervised the project. All authors interpreted the results, reviewed the manuscript and provided critical feedback. HF accepts full responsibility for the finished work and/or the conduct of the study, had access to the data, and controlled the decision to publish.

**Funding** This work is part of the initial Full Vaccine Value Assessment (iFVA) for MR-MAPs, which is funded by UNICEF and Al Waleed Philanthropies (grant number 43317323). HF, KA and MJ from the London School of Hygiene & Tropical Medicine receive funding support from Gavi, the Vaccine Alliance, and the Bill & Melinda Gates Foundation via the Vaccine Impact Modelling Consortium (grant number:

OPP1157270/INV-009125). KA is supported by the Japan Agency for Medical Research and Development (JP223fa627004).

**Disclaimer** The authors alone are responsible for the views expressed in the article and they do not necessarily represent the views, decisions or policies of the funders and the institutions with which they are affiliated.

**Competing interests** None declared.

**Patient and public involvement** Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

**Patient consent for publication** Not applicable.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data availability statement** Data are available in a public, open access repository. Measles coverage forecasts and computer codes of this analysis are publicly accessible in the GitHub repository: [https://github.com/hfu915/dynamice\\_mrmmaps](https://github.com/hfu915/dynamice_mrmmaps).

**Supplemental material** This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: <https://creativecommons.org/licenses/by/4.0/>.

#### ORCID iDs

Han Fu <http://orcid.org/0000-0002-8934-7347>

Kaja Abbas <http://orcid.org/0000-0003-0563-1576>

Stefano Malvolti <http://orcid.org/0000-0003-0146-1127>

#### REFERENCES

- Keja K, Chan C, Hayden G, *et al*. Expanded programme on immunization. *World Health Stat Q* 1988;41:59–63.
- Li X, Mukandavire C, Cucunubá ZM, *et al*. Estimating the health impact of vaccination against ten pathogens in 98 low-income and middle-income countries from 2000 to 2030: a Modelling study. *Lancet* 2021;397:398–408.
- World Health Organization. Measles vaccines: WHO position paper – April 2017. *Weekly Epidemiological Record* 2017;92:205–27.
- Causey K, Fullman N, Sorensen RJD, *et al*. Estimating global and regional disruptions to routine childhood vaccine coverage during the COVID-19 pandemic in 2020: a modelling study. *Lancet* 2021;398:522–34.
- World Health Organization. Immunization data portal [Dataset]. 2021. Available: <https://immunizationdata.who.int/listing.html> [Accessed 20 Jul 2021].
- Forster AH, Witham K, Depelseñaire ACI, *et al*. Safety, tolerability, and immunogenicity of influenza vaccination with a high-density microarray patch: results from a randomized, controlled phase I clinical trial. *PLoS Med* 2020;17:e1003024.
- The Vaccine Innovation Prioritisation Strategy. VIPS phase 2 technical NOTE: microarray patches [online]. 2020. Available: [https://www.gavi.org/sites/default/files/about/market-shaping/Phase-II/8\\_VIPS%20Phase%20II%20Technical%20Note%20Microarray%20Patches%20%28MAPs%29.pdf](https://www.gavi.org/sites/default/files/about/market-shaping/Phase-II/8_VIPS%20Phase%20II%20Technical%20Note%20Microarray%20Patches%20%28MAPs%29.pdf)
- Gavi, the Vaccine Alliance. Vaccine Microarray patches (maps): public summary of the VIPS alliance action plan. 2021.
- Richardson LC, Moss WJ. Measles and rubella microarray array patches to increase vaccination coverage and achieve measles and rubella elimination in Africa. *Pan Afr Med J* 2020;35:3.
- Hasso-Agopsowicz M, Crowcroft N, Biellik R, *et al*. Accelerating the development of measles and rubella microarray patches to eliminate measles and rubella: recent progress, remaining challenges. *Front Public Health* 2022;10:809675.

- 11 Peyraud N, Zehrunge D, Jarrhian C, *et al*. Potential use of microarray patches for vaccine delivery in low- and middle- income countries. *Vaccine* 2019;37:4427–34.
- 12 Joyce JC, Carroll TD, Collins ML, *et al*. A Microneedle patch for measles and rubella vaccination is Immunogenic and protective in infant Rhesus macaques. *J Infect Dis* 2018;218:124–32.
- 13 Measles and rubella vaccine microneedle patch phase 1-2 age de-escalation trial. 2020. Available: <https://ClinicalTrials.gov/show/NCT04394689> [Accessed 1 May 2022].
- 14 Vaxxas Pty Ltd. First-in-human study to investigate the skin tolerability of micro-projection array patches coated with live attenuated measles and rubella vaccine in healthy adult volunteers [online]. 2021. Available: <https://anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12621000820808>
- 15 Goodbye syringe? measles and rubella patch demonstrates its worth in Gambia vaccine trial. Available: <https://www.gavi.org/vaccineswork/goodbye-syringe-measles-and-rubella-patch-demonstrates-its-worth-gambia-vaccine> [Accessed 20 Sep 2023].
- 16 Newall AT, Beutels P, Tuffaha HW, *et al*. How can early stage economic evaluation help guide research for future vaccines? *Vaccine* 2022;40:175–7.
- 17 World Health Organization, United Nations Children's Fund. Measles-rubella Microarray patch (MR-MAP) target product profile [online]. 2019. Available: <https://www.who.int/publications/i/item/9789240000209> [Accessed 20 May 2020].
- 18 Hutubessy R, Lauer JA, Giersing B, *et al*. The full value of vaccine assessments (FVVA): a framework for assessing and communicating the value of vaccines for investment and introduction decision-making. *BMC Med* 2023;21.
- 19 UNICEF Office of Innovation. Vaccine microarray patches (Vmaps) [online]. Available: <https://www.unicef.org/innovation/vaccine-microarray-patches-vmaps> [Accessed 8 Aug 2023].
- 20 The World Bank. World Bank country and lending groups, 1987-2020 [online]. Available: <http://databank.worldbank.org/data/download/site-content/CLASS.xlsx> [Accessed 31 Aug 2021].
- 21 Fu H, Abbas K, Klepac P, *et al*. Effect of evidence updates on key determinants of measles vaccination impact: a Dynamic Modelling study in ten high-burden countries. *BMC Med* 2021;19:281.
- 22 Prem K, Zandvoort K van, Klepac P, *et al*. Projecting contact matrices in 177 geographical regions: an update and comparison with empirical data for the COVID-19 era. *PLoS Comput Biol* 2021;17:e1009098.
- 23 Guerra FM, Bolotin S, Lim G, *et al*. The basic reproduction number (R0) of measles: a systematic review. *Lancet Infectious Diseases* 2017;17:e420–8.
- 24 Portnoy A, Jit M, Ferrari M, *et al*. Estimates of case-fatality ratios of measles in low-income and middle-income countries: a systematic review and Modelling analysis. *Lancet Glob Health* 2019;7:e472–81.
- 25 Cata-Preta BO, Santos TM, Mengistu T, *et al*. Zero-dose children and the immunisation cascade: understanding Immunisation pathways in low and middle-income countries. *Vaccine* 2021;39:4564–70.
- 26 Hughes SL, Bolotin S, Khan S, *et al*. The effect of time since measles vaccination and age at first dose on measles vaccine effectiveness - a systematic review. *Vaccine* 2020;38:460–9.
- 27 Sudfeld CR, Navar AM, Halsey NA. Effectiveness of measles vaccination and vitamin A treatment. *Int J Epidemiol* 2010;39 Suppl 1:i48–55.
- 28 World Health Organization. Global market study: measles-containing Vaccines (MCV) [online]. 2020. Available: [https://www.who.int/immunization/programmes\\_systems/procurement/mi4a/platform/module2/Measles\\_Containing\\_Vaccines\\_Market\\_Study\\_Public\\_Summary\\_July2020.pdf?ua=1](https://www.who.int/immunization/programmes_systems/procurement/mi4a/platform/module2/Measles_Containing_Vaccines_Market_Study_Public_Summary_July2020.pdf?ua=1)
- 29 Ko M, Malvoti S, Cherian T, *et al*. Estimating the future global dose demand for measles-rubella microarray patches. *Front Public Health* 2022;10:1037157.
- 30 The World Bank. GDP deflator (base year varies by country). Available: <https://data.worldbank.org/indicator/NY.GDP.DEFL.ZS> [Accessed 30 Nov 2021].
- 31 Turner HC, Lauer JA, Tran BX, *et al*. Adjusting for inflation and currency changes within health economic studies. *Value Health* 2019;22:1026–32.
- 32 World Health Organization. Mi4A vaccine purchase database. Available: [https://cdn.who.int/media/docs/default-source/immunization/mi4a/mi4a\\_public\\_database.xlsx?sfvrsn=1adc791a\\_11](https://cdn.who.int/media/docs/default-source/immunization/mi4a/mi4a_public_database.xlsx?sfvrsn=1adc791a_11) [Accessed 6 Dec 2021].
- 33 Levin A, Burgess C, Garrison LP Jr, *et al*. Global eradication of measles: an epidemiologic and economic evaluation. *J Infect Dis* 2011;204 Suppl 1:S98–106.
- 34 World Health Organization. WHO guide for standardization of economic evaluations of immunization programmes. 2019. Available: <https://apps.who.int/iris/bitstream/handle/10665/329389/WHO-IVB-19.10-eng.pdf?ua=1> [Accessed 7 Apr 2021].
- 35 Bertram MY, Lauer JA, De Joncheere K, *et al*. Cost-effectiveness thresholds: pros and cons. *Bull World Health Organ* 2016;94:925–30.
- 36 Lomas J, Claxton K, Ochalek J. Accounting for country- and time-specific values in the economic evaluation of health-related projects relevant to low- and middle-income countries. *Health Policy Plan* 2022;37:45–54.
- 37 Ochalek J, Lomas J. Reflecting the health opportunity costs of funding decisions within value frameworks: initial estimates and the need for further research. *Clin Ther* 2020;42:44–59.
- 38 Adhikari BB, Goodson JL, Chu SY, *et al*. Assessing the potential cost-effectiveness of microneedle patches in childhood measles vaccination programs: the case for further research and development. *Drugs R D* 2016;16:327–38.
- 39 Local Burden of Disease Vaccine Coverage Collaborators. Mapping routine measles vaccination in low- and middle-income countries. *Nature* 2021;589:415–9.
- 40 Enanoria WTA, Liu F, Zipprich J, *et al*. The effect of contact investigations and public health interventions in the control and prevention of measles transmission: a simulation study. *PLoS One* 2016;11:e0167160.
- 41 Haacker M, Hallett TB, Atun R. On discount rates for economic evaluations in global health. *Health Policy Plan* 2020;35:107–14.
- 42 Thokala P, Ochalek J, Leech AA, *et al*. Cost-effectiveness thresholds: the past, the present and the future. *Pharmacoeconomics* 2018;36:509–22.
- 43 World Health Organization. WHO evidence considerations for vaccine policy development (ECVP): generic framework for vaccines/ monoclonal antibodies in development. 2022. Available: <https://www.who.int/publications/m/item/who-evidence-considerations-for-vaccine-policy-development-ecvp> [Accessed 16 Oct 2022].
- 44 Kochhar S, Barreira D, Beattie P, *et al*. Building the concept for WHO evidence considerations for vaccine policy (ECVP): tuberculosis vaccines intended for adults and adolescents as a test case. *Vaccine* 2022;40:1681–90.